Retatrutide: Benefits & Research
Part of the Retatrutide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Why Retatrutide Is the Most Closely Watched Obesity Drug of the Decade
Retatrutide (LY3437943) is Eli Lilly's once-weekly triple agonist of GLP-1, GIP, and glucagon receptors. Its Phase 2 obesity data, published in The New England Journal of Medicine in June 2023, produced the largest mean weight loss ever recorded in a controlled anti-obesity trial — and the curve had not yet plateaued at 48 weeks.[1]
Mechanistically, retatrutide attacks obesity from three pathways simultaneously:
- GLP-1 receptor agonism — appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion (same primary mechanism as semaglutide).
- GIP receptor agonism — additional satiety signaling and improved fat metabolism (same as tirzepatide's second mechanism).
- Glucagon receptor agonism — increased energy expenditure and direct hepatic fat oxidation (the key differentiator vs all other approved or late-stage anti-obesity drugs).
This three-pathway approach is what produces both the record weight-loss numbers and the distinctive MASH (liver disease) efficacy below.
Record-Setting Weight Loss (Phase 2 NEJM 2023)
The Jastreboff Phase 2 obesity trial randomized 338 adults with obesity (BMI ≥27 kg/m² with weight-related comorbidity, or BMI ≥30) to retatrutide or placebo for 48 weeks:[1]
| Dose | Mean weight loss | ≥10% lost | ≥15% lost | ≥20% lost | ≥25% lost |
|---|---|---|---|---|---|
| 1 mg | -7.2% | 32% | 15% | 13% | 4% |
| 4 mg | -17.1% | 83% | 57% | 40% | 22% |
| 8 mg | -22.8% | 92% | 83% | 60% | 48% |
| 12 mg | -24.2% | 94% | 83% | 63% | 48% |
| Placebo | -2.1% | 9% | 2% | 0% | 0% |
Critical context: the 12 mg group's weight-loss curve was still declining at 48 weeks — patients were continuing to lose weight. This is unusual for anti-obesity drugs, which typically plateau by 12–18 months. Phase 3 trials with longer follow-up will tell us where the plateau ultimately lies for retatrutide — it may exceed 30% mean weight loss at the highest dose with sufficient duration.
Comparison to other GLP-1 family drugs (different trials, similar populations)
- Semaglutide 2.4 mg (STEP-1, 68 weeks): ~14.9% mean weight loss.
- Tirzepatide 15 mg (SURMOUNT-1, 72 weeks): ~22.5% mean weight loss.
- Retatrutide 12 mg (Phase 2, 48 weeks): ~24.2% — and not plateaued.
MASH / Liver Fat: Dramatic Phase 2 Sub-Study Results
A sub-study of the obesity Phase 2 examined liver fat content via MRI-PDFF in patients with NAFLD/MASH (metabolic dysfunction-associated steatohepatitis) at baseline. Results were striking:[4]
- 82% mean relative reduction in liver fat content at the 8 mg retatrutide dose at 48 weeks.
- 86% of NAFLD patients achieved complete liver fat resolution (defined as < 5% liver fat content) at the 8 mg dose.
- The relative liver fat reduction at the highest retatrutide dose was substantially greater than any currently approved or late-stage MASH drug.
Mechanism: the glucagon receptor component directly stimulates hepatic fatty acid oxidation in liver cells, which neither pure GLP-1 agonists nor GLP-1/GIP co-agonists do. This is the same mechanism behind survodutide's MASH activity, but retatrutide produces larger magnitude effects in the available data.
A dedicated Phase 3 MASH trial is ongoing as of 2026.
Type 2 Diabetes (Phase 2 Lancet 2023)
The companion Phase 2 trial in 281 patients with type 2 diabetes was published in The Lancet in 2023.[2] At 36 weeks:
- HbA1c reduction of −2.02 percentage points at the highest dose — among the largest HbA1c reductions reported for any T2D drug.
- Mean weight loss of −16.9% at 12 mg over 36 weeks (less duration than the obesity trial).
- Improved fasting glucose, postprandial glucose, and insulin sensitivity measures across all active arms.
- Active comparator in the trial was dulaglutide; retatrutide produced superior glycemic control and weight loss.
The retatrutide T2D Phase 3 program is anticipated to read out in 2026–2027 alongside the obesity TRIUMPH trials.
Cardiometabolic Markers
Beyond weight and HbA1c, Phase 2 trials documented broad cardiometabolic improvements:
- Blood pressure: -3 to -6 mmHg systolic and diastolic at the higher doses.
- Triglycerides: substantial reduction (-30% or more at high doses).
- LDL cholesterol: modest reduction.
- HDL cholesterol: modest increase.
- C-reactive protein: reduction (inflammatory marker).
- Waist circumference: substantial reduction proportional to weight loss.
One signal warrants caveat: resting heart rate increased by 5–7 bpm at the highest doses — larger than semaglutide (+2 bpm) or tirzepatide (+3 bpm). The long-term cardiovascular implications of this signal will be characterized by the ongoing Phase 3 cardiovascular outcomes trials.
Retatrutide vs. Semaglutide vs. Tirzepatide
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + glucagon (triple) |
| FDA approval | Yes (Wegovy / Ozempic) | Yes (Zepbound / Mounjaro) | No — Phase 3 |
| Peak weight loss (Phase 3) | 14.9% (STEP-1, 68 wks) | 22.5% (SURMOUNT-1, 72 wks) | ~24.2% at 48 wks Phase 2 (not plateaued) |
| Direct liver fat activity | Modest (~17%) | Modest | Large (~82%) |
| Heart rate increase | +2 bpm | +3 bpm | +5–7 bpm |
| Cardiovascular outcomes data | SELECT trial positive | Phase 3 ongoing | Phase 3 ongoing |
| Frequency | Weekly SC | Weekly SC | Weekly SC |
See retatrutide vs tirzepatide and retatrutide vs semaglutide for detailed head-to-head comparisons.